Diabetes und Leber

Schlüsselwörter

Diabetes mellitus - nicht-alkoholische Fettlebererkrankung - Krebs

Keywords

diabetes mellitus - non-alcoholic fatty liver disease - cancer

• Literatur

• 1 Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; 1 CD007340
• 2 Chung JS, Park S, Park SH et al. Overexpression of Romo1 promotes production of reactive oxygen species and invasiveness of hepatic tumor cells. Gastroenterology 2012; 143: 1084-1094
• 3 Farese RV, Zechner R, Newgard CB et al. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 2012; 15: 579-573
• 4 Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 2011; 15: 1325-1365
• 5 Herzig S, Vegiopoulos A. Obesity, Diabetes and cancer. Adipositas 2012; b 1: 1-5
• 6 Herzig S. Liver: A target of late diabetic complications. Exp Clin Endocrinol Diabetes 2012; 120: 202-204
• 7 Kacerovsky M, Brehm A, Chmelik M et al. Insulin resistance relates to impairment of muscular mitochondrial ATP synthesis in type 1 diabetes mellitus. J Intern Med 2011; 269: 189-199
• 8 Kulozik Ph, Jones A, Mattijssen F et al. Hepatic deficiency in transcriptional co-factor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab 2011; 13: 389-400
• 9 Musso G, Cassader M, Rosina F et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD). Diabetologia 2012; 55: 885-904
• 10 ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328
• 11 Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208
• 12 Phielix E, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci 2011; 32: 607-616
• 13 Rathmann W, Scheidt-Nave C, Roden M et al. Type 2 diabetes: prevalence and relevance of genetic and acquired factors for its prediction. Dtsch Arztebl Int 2013; im Druck
• 14 Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-348
• 15 Sharma D, Wang J, Fu PP et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010; 52: 1713-22
• 16 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma – two growing epidemics with a potential link. Cancer 2009; 115: 5651-5661
• 17 Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus. Nat Rev Endocrinol 2011; 7: 456-465
• 18 Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2011; 13: 92-103
• 19 Targher G, Bertolini L, Padovani R et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53: 713-718
• 20 Wu Y, Brodt P, Sun H et al. Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 2010; 70: 57-67